Scarica l'app Stockscreener
0.4006
5.54%
-0.0235
Dopo l'orario di chiusura:
.40
-0.0006
-0.15%
Precedente Chiudi:
$0.4241
Aprire:
$0.3688
Volume 24 ore:
1.35M
Relative Volume:
0.80
Capitalizzazione di mercato:
$23.55M
Reddito:
-
Utile/perdita netta:
$-123.46M
Rapporto P/E:
-0.1547
EPS:
-2.59
Flusso di cassa netto:
$-104.11M
1 W Prestazione:
-29.43%
1M Prestazione:
-50.54%
6M Prestazione:
+3.22%
1 anno Prestazione:
-28.46%
Intervallo 1D:
$0.36
$0.4178
Intervallo di 1 settimana:
$0.36
$0.62
Portata 52W:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Confronta BCAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4006 | 24.93M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-06-28 | Iniziato | ROTH Capital | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | BTIG Research | Buy |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | JP Morgan | Overweight |
| 2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - ulpravda.ru
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - ulpravda.ru
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - ulpravda.ru
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - ulpravda.ru
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 20252026 world cup usa national team round of 16 defensive leaders possession football winner prediction guide - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com India
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - Defense World
Can BioAtla Inc. stock reach $100 price targetGap Up & Safe Swing Trade Setup Alerts - Улправда
Aug Drivers: Why retail investors pile into BioAtla Inc. stockInsider Selling & Weekly Watchlist of Top Performers - Улправда
Why retail investors pile into BioAtla Inc. stockTrade Volume Report & Technical Pattern Alert System - Улправда
How rising interest rates impact BioAtla Inc. stock2025 Bull vs Bear & Weekly Momentum Stock Picks - DonanımHaber
Can BioAtla Inc. stock rebound after recent weakness2025 Analyst Calls & Verified Stock Trade Ideas - Улправда
Can BioAtla Inc. stock resist market sell offsEarnings Overview Report & Daily Entry Point Alerts - Улправда
BioAtla Earnings Notes - Trefis
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
BioAtla (NASDAQ: BCAB) seeks approval for stock issuance and reverse split - Stock Titan
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):